325 related articles for article (PubMed ID: 8620506)
1. Changes in cellular components of spleen and lymph node cells and the effector cells responsible for Meth A tumor eradication induced by zinostatin stimalamer.
Masuda E; Maeda H
Cancer Res; 1996 Apr; 56(8):1868-73. PubMed ID: 8620506
[TBL] [Abstract][Full Text] [Related]
2. Antitumor resistance induced by zinostatin stimalamer (ZSS), a polymer-conjugated neocarzinostatin (NCS) derivative. I. Meth A tumor eradication and tumor-neutralizing activity in mice pretreated with ZSS or NCS.
Masuda E; Maeda H
Cancer Immunol Immunother; 1995 May; 40(5):329-38. PubMed ID: 7600566
[TBL] [Abstract][Full Text] [Related]
3. Changes in cellular composition induced by neocarzinostatin pretreatment in Meth A-bearing mice and the responsible antitumor effector cells.
Masuda E; Shishido T; Fujimoto R; Maeda H
Immunopharmacology; 1997 Aug; 37(1):105-16. PubMed ID: 9285249
[TBL] [Abstract][Full Text] [Related]
4. Regulatory role of T lymphocytes and NK cells in tumor allograft development.
Sobotková E; Nouza K
Neoplasma; 1993; 40(2):75-80. PubMed ID: 8350958
[TBL] [Abstract][Full Text] [Related]
5. [Antitumor effects of a new antitumor agent, zinostatin stimalamer (YM881)--effects on experimental tumors in vitro and in vivo].
Numasaki Y; Takahashi K; Masuda E; Nohara C; Maeda H
Gan To Kagaku Ryoho; 1991 Oct; 18(13):2289-94. PubMed ID: 1834021
[TBL] [Abstract][Full Text] [Related]
6. Successful adoptive immunotherapy of murine poorly immunogenic tumor with specific effector cells generated from gene-modified tumor-primed lymph node cells.
Tanaka H; Yoshizawa H; Yamaguchi Y; Ito K; Kagamu H; Suzuki E; Gejyo F; Hamada H; Arakawa M
J Immunol; 1999 Mar; 162(6):3574-82. PubMed ID: 10092816
[TBL] [Abstract][Full Text] [Related]
7. Importance of Lyt-2+ T-cells in the resistance of melphalan-cured MOPC-315 tumor bearers to a challenge with MOPC-315 tumor cells.
Barker E; Mokyr MB
Cancer Res; 1988 Sep; 48(17):4834-42. PubMed ID: 3261626
[TBL] [Abstract][Full Text] [Related]
8. Antitumor activity of orally administered SMANCS, a polymer-conjugated protein drug, in mice bearing various murine tumors.
Schmitt DA; Kisanuki K; Kimura S; Oka K; Pollard RB; Maeda H; Suzuki F
Anticancer Res; 1992; 12(6B):2219-24. PubMed ID: 1295469
[TBL] [Abstract][Full Text] [Related]
9. Interleukin 18 induces the sequential activation of natural killer cells and cytotoxic T lymphocytes to protect syngeneic mice from transplantation with Meth A sarcoma.
Micallef MJ; Tanimoto T; Kohno K; Ikeda M; Kurimoto M
Cancer Res; 1997 Oct; 57(20):4557-63. PubMed ID: 9377569
[TBL] [Abstract][Full Text] [Related]
10. Role of natural killer cells and macrophages in the nonspecific resistance to tumors in mice stimulated with SMANCS, a polymer-conjugated derivative of neocarzinostatin.
Suzuki F; Pollard RB; Uchimura S; Munakata T; Maeda H
Cancer Res; 1990 Jul; 50(13):3897-904. PubMed ID: 2141295
[TBL] [Abstract][Full Text] [Related]
11. [Activation and regulation of macrophages induced by inoculation of cryodestroyed tumor cells].
Tsujino M
Osaka Daigaku Shigaku Zasshi; 1990 Jun; 35(1):180-205. PubMed ID: 2135404
[TBL] [Abstract][Full Text] [Related]
12. Augmentation of in vitro interleukin 10 production after in vivo administration of interleukin 18 is activated macrophage-dependent and is probably not involved in the antitumor effects of interleukin 18.
Micallef MJ; Tanimoto T; Kohno K; Ikeda M; Ikegami H; Kurimoto M
Anticancer Res; 1998; 18(6A):4267-74. PubMed ID: 9891477
[TBL] [Abstract][Full Text] [Related]
13. Detection and characterization of anti-tumour effector cells in Meth-A-bearing mice treated with recombinant human interleukin 2.
Naruo KI; Hinuma S; Shiho O; Houkan T; Ootsu K; Tsukamoto K
Clin Exp Immunol; 1989 May; 76(2):278-83. PubMed ID: 2788049
[TBL] [Abstract][Full Text] [Related]
14. An increase in mouse tumor growth by an in vivo immunomodulating effect of titanium dioxide nanoparticles.
Moon EY; Yi GH; Kang JS; Lim JS; Kim HM; Pyo S
J Immunotoxicol; 2011; 8(1):56-67. PubMed ID: 21288165
[TBL] [Abstract][Full Text] [Related]
15. Response of T and B lymphocytes in the spleen, lymph nodes and mammary tumors in rats treated with human soluble tumor-associated antigens and commercial human albumin.
Ben-Hur H; Kossoy G; Mehrdad H; Elhayany A; Zusman I
Oncol Rep; 2004 Dec; 12(6):1329-33. PubMed ID: 15547759
[TBL] [Abstract][Full Text] [Related]
16. Antitumor activity of astaxanthin and its mode of action.
Jyonouchi H; Sun S; Iijima K; Gross MD
Nutr Cancer; 2000; 36(1):59-65. PubMed ID: 10798217
[TBL] [Abstract][Full Text] [Related]
17. [Anticancer effects of OK-432 (2). Anticancer actions of M phi activated by OK-432].
Saito M; Aonuma E; Noda T; Nakadate I; Nanjo M; Ebina T; Ishida N
Gan To Kagaku Ryoho; 1983 May; 10(5):1363-71. PubMed ID: 6870302
[TBL] [Abstract][Full Text] [Related]
18. Studies on the mechanisms of action of the immunomodulator Bestatin in various screening test systems.
Schorlemmer HU; Bosslet K; Dickneite G; Lüben G; Sedlacek HH
Behring Inst Mitt; 1984 May; (74):157-73. PubMed ID: 6383322
[TBL] [Abstract][Full Text] [Related]
19. Mechanisms of the potentiation of specific antitumor immunity by intratumor injection of Corynebacterium parvum.
Miyata H; Himeno K; Nomoto K
Cancer Res; 1983 Oct; 43(10):4670-5. PubMed ID: 6883325
[TBL] [Abstract][Full Text] [Related]
20. Cytotoxic T-cell-mediated antitumor effect of levamisole against murine syngeneic fibrosarcoma.
Gomi K; Morimoto M; Nomoto K
Cancer Res; 1982 Oct; 42(10):4197-202. PubMed ID: 6980702
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
